1,000+ Opportunities
Find the right grant
Search federal, foundation, and corporate grants with AI — or browse by agency, topic, and state.
This listing may be outdated. Verify details at the official source before applying.
Find similar grantsPrivate Foundation Grants for Research in Chronic Pain and Mental Health is sponsored by Foundation for the Advancement of Psychedelic Therapy (FAPT). FAPT supports research and development in psychedelic-assisted therapy, focusing on chronic pain and mental health.
Get a weekly digest of new grants like this
A free weekly digest of new foundation and federal funding opportunities as they're added to Granted. Unsubscribe anytime.
Or search similar grants →According to the current listing, eligibility includes: Academic institutions and private companies exploring therapeutic applications of psychedelics. Confirm the full requirements in the official notice before applying.
Private Foundation Grants for Research in Chronic Pain and Mental Health is funded by Foundation for the Advancement of Psychedelic Therapy (FAPT). Verify program details on the funder's official page before applying.
Start from the official opportunity page linked in this listing — it carries the sponsor's submission instructions.
The FY2026 Rural Health Network Advancement Program (HRSA-26-082) offers six awards of roughly $500,000 to help independent rural hospitals and clinics form integrated networks without surrendering local ownership. With a July 24, 2026 deadline and a pilot design that rewards genuine collaboration over merger, here is who qualifies, what a fundable network looks like, and how small rural providers should approach it.
Read articleBioStabilization Systems funds multi-party consortia under Other Transaction Authority across four phases, with hard down-selects that punish single-investigator labs and reward biotech-academic teams already deep into bioprocessing.
Read articleARPA-H selected 13 research teams for EVIDENT, a $139.4M initiative to develop objective clinical endpoints for rapid-acting behavioral health therapies including psilocybin. At least $50M will match state psychedelic research investments under a Trump executive order.
Read article